Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma

Neurology

Volumn 83, Issue 3, 2014, Pages 227-234

  Bähr, Oliver ^a,b   Harter, Patrick N ^a,b   Weise, Lutz M ^a,b   You, Se Jong ^a,b   Mittelbronn, Michel ^a,b   Ronellenfitsch, Michael W ^a,b   Rieger, Johannes ^a,b   Steinbach, Joachim P ^a,b   Hattingen, Elke ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, PHARMACOLOGICAL; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84905820690     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000594     Document Type: Article

References (21)

1. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-242.
2. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-1206.
3. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787.
4. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91:329-336.
5. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101:319-323.
6. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
7. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
8. Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76:432-437.
9. Wick A, Dorner N, Schafer N, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011;69:586-592.
10. DeLay M, Jahangiri A, Carbonell WS, et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 2012; 18:2930-2942.
11. Hu YL, DeLay M, Jahangiri A, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 2012;72:1773-1783.
12. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011; 108:3749-3754.
13. Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2009; 99:49-56.
14. Rieger J, Bahr O, Ronellenfitsch MW, Steinbach J, Hattingen E. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia? J Clin Oncol 2010;28:e477.
15. Mong S, Ellingson BM, Nghiemphu PL, et al. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 2012;33:1763-1770.
16. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010;28: e91-e93.
17. Bähr O, Hattingen E, Rieger J, Steinbach JP. Bevacizumabinduced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol 2011;13: 1020-1029.
18. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963-1972.
19. Meloan SN, Puchtler H, Valentine LS. Alkaline and acid alizarin red S stains for alkali-soluble and alkali-insoluble calcium deposits. Arch Pathol 1972;93:190-197.
20. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
21. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-6628..